CA3037581A1 - Terlipressin compositions and their methods of use - Google Patents
Terlipressin compositions and their methods of use Download PDFInfo
- Publication number
- CA3037581A1 CA3037581A1 CA3037581A CA3037581A CA3037581A1 CA 3037581 A1 CA3037581 A1 CA 3037581A1 CA 3037581 A CA3037581 A CA 3037581A CA 3037581 A CA3037581 A CA 3037581A CA 3037581 A1 CA3037581 A1 CA 3037581A1
- Authority
- CA
- Canada
- Prior art keywords
- terlipressin
- administered
- capsule
- dosage form
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662410971P | 2016-10-21 | 2016-10-21 | |
| US62/410,971 | 2016-10-21 | ||
| US201762472291P | 2017-03-16 | 2017-03-16 | |
| US62/472,291 | 2017-03-16 | ||
| PCT/US2017/057601 WO2018075897A1 (en) | 2016-10-21 | 2017-10-20 | Terlipressin compositions and their methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3037581A1 true CA3037581A1 (en) | 2018-04-26 |
Family
ID=62019439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3037581A Pending CA3037581A1 (en) | 2016-10-21 | 2017-10-20 | Terlipressin compositions and their methods of use |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10993984B2 (cg-RX-API-DMAC10.html) |
| EP (2) | EP4516803A3 (cg-RX-API-DMAC10.html) |
| JP (3) | JP2020500164A (cg-RX-API-DMAC10.html) |
| AU (2) | AU2017345720B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3037581A1 (cg-RX-API-DMAC10.html) |
| ES (1) | ES3023754T3 (cg-RX-API-DMAC10.html) |
| IL (2) | IL265761B2 (cg-RX-API-DMAC10.html) |
| MA (1) | MA46586A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2018075897A1 (cg-RX-API-DMAC10.html) |
| ZA (1) | ZA201901912B (cg-RX-API-DMAC10.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2678833C2 (ru) | 2008-09-17 | 2019-02-04 | Киазма Инк. | Фармацевтические композиции и соответствующие способы доставки |
| SI3253401T1 (sl) | 2015-02-03 | 2025-07-31 | Amryt Endo, Inc. | Zdravljenje akromegalije z oralnim oktreotidom |
| CN109223720B (zh) * | 2018-09-12 | 2020-11-27 | 南京康舟医药科技有限公司 | 注射用醋酸特利加压素冻干粉针剂的制备方法 |
| US20230399360A1 (en) * | 2019-12-20 | 2023-12-14 | Northwestern University | Terlipressin-octadecanedioic acid conjugate for vasoconstrictive therapy |
| US11141457B1 (en) | 2020-12-28 | 2021-10-12 | Amryt Endo, Inc. | Oral octreotide therapy and contraceptive methods |
| CN114306250B (zh) * | 2021-11-26 | 2023-07-14 | 苏州天马医药集团天吉生物制药有限公司 | 一种醋酸特利加压素制剂及其制备方法 |
| CA3238277A1 (en) * | 2022-01-13 | 2023-07-20 | David Caron | Oral dosage forms |
| US20240156895A1 (en) * | 2022-10-28 | 2024-05-16 | Mallinckrodt Pharmaceuticals Ireland Limited | Compositions for improving kidney function in patients with hepatorenal syndrome |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH455823A (de) | 1964-08-01 | 1968-05-15 | Ceskoslovenska Akademie Ved | Verfahren zur Herstellung von Peptiden |
| EP1188443A1 (en) | 2000-09-15 | 2002-03-20 | Ferring BV | Improved protocol for paracentesis |
| JO2937B1 (en) | 2004-08-11 | 2016-03-15 | فيرينغ.بي.في | Tight muscles of the peptide vascular tensioner receptor |
| US8883965B2 (en) | 2006-02-10 | 2014-11-11 | Ferring B.V. | Compounds |
| GB2438834A (en) | 2006-06-08 | 2007-12-12 | Optinose As | Intranasal protein administration |
| US7960336B2 (en) * | 2007-08-03 | 2011-06-14 | Pharmain Corporation | Composition for long-acting peptide analogs |
| RU2678833C2 (ru) * | 2008-09-17 | 2019-02-04 | Киазма Инк. | Фармацевтические композиции и соответствующие способы доставки |
| AU2015201581B2 (en) * | 2008-09-17 | 2017-03-09 | Amryt Endo, Inc. | Pharmaceutical Compositions and Related Methods of Delivery |
| WO2011116139A2 (en) * | 2010-03-16 | 2011-09-22 | Chiasma Inc. | Improved pharmaceutical compositions and methods of delivery |
| WO2014165607A2 (en) * | 2013-04-02 | 2014-10-09 | Stealth Peptides International, Inc. | Aromatic-cationic peptide formulations, compositions and methods of use |
| JO3371B1 (ar) | 2013-07-26 | 2019-03-13 | Ferring Bv | ناهضات مستقبل فاسوبريسين 2 |
| AU2015335855A1 (en) * | 2014-10-24 | 2017-05-18 | Mallinckrodt Hospital Products IP Limited | Method of treating patients with hepatorenal syndrome type 1 |
| AU2016240068B9 (en) | 2015-03-30 | 2020-07-30 | Sunnybrook Research Institute | Method for treating cancer |
| JP2017014206A (ja) | 2015-06-30 | 2017-01-19 | ナノアンティバイオティクス，インコーポレイテッド | 腹水の治療 |
-
2017
- 2017-10-20 MA MA046586A patent/MA46586A/fr unknown
- 2017-10-20 EP EP25152377.5A patent/EP4516803A3/en active Pending
- 2017-10-20 AU AU2017345720A patent/AU2017345720B2/en active Active
- 2017-10-20 IL IL265761A patent/IL265761B2/en unknown
- 2017-10-20 IL IL313083A patent/IL313083A/en unknown
- 2017-10-20 US US16/343,232 patent/US10993984B2/en active Active
- 2017-10-20 EP EP17862085.2A patent/EP3528828B1/en active Active
- 2017-10-20 JP JP2019521093A patent/JP2020500164A/ja not_active Withdrawn
- 2017-10-20 ES ES17862085T patent/ES3023754T3/es active Active
- 2017-10-20 CA CA3037581A patent/CA3037581A1/en active Pending
- 2017-10-20 WO PCT/US2017/057601 patent/WO2018075897A1/en not_active Ceased
-
2019
- 2019-03-27 ZA ZA2019/01912A patent/ZA201901912B/en unknown
-
2021
- 2021-11-11 US US17/524,022 patent/US20220313773A1/en not_active Abandoned
-
2023
- 2023-06-30 JP JP2023108121A patent/JP2023120445A/ja not_active Withdrawn
- 2023-10-27 AU AU2023255036A patent/AU2023255036B2/en active Active
-
2024
- 2024-01-31 US US18/429,227 patent/US20250000933A1/en active Pending
- 2024-11-06 JP JP2024194379A patent/JP2025020319A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017345720B2 (en) | 2023-07-27 |
| IL265761B1 (en) | 2024-07-01 |
| JP2023120445A (ja) | 2023-08-29 |
| US10993984B2 (en) | 2021-05-04 |
| EP4516803A3 (en) | 2025-06-25 |
| AU2023255036B2 (en) | 2026-06-18 |
| EP3528828B1 (en) | 2025-01-29 |
| US20250000933A1 (en) | 2025-01-02 |
| JP2025020319A (ja) | 2025-02-12 |
| AU2023255036A1 (en) | 2023-11-16 |
| AU2017345720A1 (en) | 2019-04-11 |
| JP2020500164A (ja) | 2020-01-09 |
| NZ751717A (en) | 2025-05-02 |
| IL265761A (en) | 2019-06-30 |
| US20190240284A1 (en) | 2019-08-08 |
| ES3023754T3 (en) | 2025-06-03 |
| IL313083A (en) | 2024-07-01 |
| EP4516803A2 (en) | 2025-03-05 |
| IL265761B2 (en) | 2024-11-01 |
| MA46586A (fr) | 2019-08-28 |
| WO2018075897A1 (en) | 2018-04-26 |
| EP3528828A1 (en) | 2019-08-28 |
| US20220313773A1 (en) | 2022-10-06 |
| ZA201901912B (en) | 2023-10-25 |
| EP3528828A4 (en) | 2020-07-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250000933A1 (en) | Terlipressin compositions and their methods of use | |
| JP4659358B2 (ja) | 経口インスリン療法 | |
| AU2016326749B2 (en) | Methods for producing stable therapeutic glucagon formulations in aprotic polar solvents | |
| RS66595B1 (sr) | Puferisane formulacije eksendina (9-39) | |
| US9592208B2 (en) | Formulations comprising 2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol | |
| WO2008098212A2 (en) | Extended release formulations of glucagon and other peptides and proteins | |
| TW201039840A (en) | Composition for the treatment of prostate cancer | |
| TW201249463A (en) | Pharmaceutical formulations | |
| JP2024523580A (ja) | 肝疾患治療の組合せ療法 | |
| CN116173188B (zh) | 口服glp-1类似物固体脂质纳米粒及其制备方法和应用 | |
| KR20150114505A (ko) | 불용성 코르티코스테로이드 및 수용성 코르티코스테로이드를 포함하는 약학적 제형 | |
| AU2025271571A1 (en) | Intranasal formulations and delivery of somatostatin mimetics and uses thereof | |
| US20170281607A1 (en) | Pharmaceutical compositions and methods for the treatment of diabetes | |
| KR20230026984A (ko) | 비양성자성의 극성 용매 중의 안정한 지속 방출성 치료 조성물 및 그의 제조 방법 | |
| US12005049B2 (en) | Methods of preventing cancer metastasis | |
| KR20120138229A (ko) | 정맥내 투여용 이부프로펜을 이용한 중증 환자의 치료 | |
| HK40120596A (en) | Terlipressin compositions and their methods of use | |
| HK40014065B (en) | Terlipressin composition for use in treating ascites | |
| HK40014065A (en) | Terlipressin composition for use in treating ascites | |
| US12343383B2 (en) | High concentration insulin formulation | |
| WO2023245470A1 (zh) | Mdp类似物在制备用于治疗炎症性肠病的药物中的用途 | |
| CN117298247A (zh) | Mdp类似物在制备用于治疗炎症性肠病的药物中的用途 | |
| WO2024182079A1 (en) | Veterinary formulation of metronidazole, and related methods | |
| HK40101667A (en) | Methods for producing stable therapeutic formulations in aprotic polar solvents | |
| HK40101667B (en) | Methods for producing stable therapeutic formulations in aprotic polar solvents |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220705 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241011 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241011 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241011 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20241217 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20250401 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250404 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250716 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250716 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE Effective date: 20250718 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250718 |
|
| R14 | Transfer of ownership recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250721 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251007 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251007 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260505 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260506 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260728 |